Delivery Order SPE2DB20D2104-SPE2DB25FMXPX
- Not listed
- The Defense Logistics Agency awarded a $23,756.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Entresto 49 mg-51 mg tablets (60-count packages). The contract, which represents a non-set-aside competitive award, specifies a place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a firm fixed-price delivery order valued at approximately $29,940 by the Defense Logistics Agency on August 4, 2025. The contract calls for the delivery of 180 tablets of Entresto 24 mg-26 mg, a prescription medication used to treat heart failure, with an ultimate completion date of August 5, 2025. This is an unset-aside, competitively awarded delivery order executed under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Entresto 24 mg-26 mg tablets (180-count units) with a contract value of $2,091.35 and an ultimate completion date of July 31, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $14,010.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count units). The contract, which is not set-aside and was competitively awarded, has an ultimate completion date of July 31, 2025. AmerisourceBergen Drug Corp will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order valued at $3,938.60 to AmerisourceBergen Drug Corp for the supply of Entresto 97 mg-103 mg tablets (180 count) on July 28, 2025, with an ultimate completion date of July 29, 2025. This firm fixed-price delivery order was awarded on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Entresto 24 mg-26 mg tablets (180 count) valued at $10,734.17. This firm fixed-price, competitively awarded contract is scheduled for completion by August 18, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,718.16 to AmerisourceBergen Drug Corp for the supply of Entresto 97 mg-103 mg tablets (180-count units). This firm fixed-price delivery order, awarded on July 31, 2025, represents a non-set-aside competitive procurement with an ultimate completion date of August 1, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,214.04 firm fixed price delivery order for Entresto 24 mg-26 mg tablets (60-count) on July 29, 2025, with completion scheduled for July 30, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a delivery order valued at approximately $24,925 to AmerisourceBergen Drug Corp for the supply of Entresto 24 mg-26 mg tablets (180 count) under a firm fixed-price contract. The award was made on August 15, 2025, with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical delivery order....
- The Defense Logistics Agency awarded a delivery order valued at $2,012.66 to AmerisourceBergen Drug Corp for the supply of Entresto 49 mg-51 mg tablets (180-count package). This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 18, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a ceiling value of $999.999...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXPXDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a $6,748.34 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on August 12, 2025, for the supply of Entresto 24 mg-26 mg tablets (180-count). The contract, which is non-set-aside and competitively awarded, specifies a place of performance in Conshohocken, PA, with an ultimate completion date of August 13, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio includes brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. All reviewed contract awards demonstrate the company's capability to meet federal procurement requirements through open competition, with delivery orders consistently featuring firm fixed pricing and ranging from small-value transactions to substantial orders exceeding $45,000, showcasing its versatility in fulfilling diverse federal medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 8/12/25 |